This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Interventions
The two regimens under examination were ciprofloxacin 400 mg intravenously (IV) every 12 hours plus metronidazole 500 mg IV every 6 hours versus piperacillin-tazobactam 3.375 g IV every 6 hours. Conversion to oral antibiotics was allowed after 48 hours if the patients had improved clinically.
Location/setting
USA/hospital.
Methods

Analytical approach:
This economic evaluation was based on a single study, the data from which were used to populate a decision tree. The time horizon of the analysis was restricted to the in-hospital stay. The authors stated that the perspective of the hospital was adopted in the study.
Effectiveness data:
The clinical data came from a multi-centre (34 medical institutions), blinded, randomised clinical trial (RCT), in which patients were treated for a maximum of 14 days and further followed for a maximum of 5 weeks post-therapy. Of the 459 patients included in the intention to treat analysis, 244 (131 in the ciprofloxacin-metronidazole group and 113 in the piperacillin-tazobactam group) were included in this economic evaluation. The two groups were similar in terms of their demographic and clinical characteristics. Sub-group analyses were performed for patients with or without appendicitis and for those able or unable to receive oral antibiotics. The key clinical outcome was the success rate with consequent switch to oral antibiotics.
Monetary benefit and utility valuations:
None.
Measure of benefit:
The summary benefit measure was the success rate. This was estimated directly from the RCT.
